CHICAGO–(BUSINESS WIRE)–April 26, 2005–The Physicians
Interactive Group of Allscripts (Nasdaq:MDRX), the leading provider of
clinical software, connectivity and information solutions that
physicians use to improve healthcare, today announced their selection
by Boehringer Ingelheim Pharmaceuticals, Inc (BIPI) to be the
preferred provider of e-Detailing services across multiple therapeutic
areas. The Physicians Interactive Group of Allscripts has established
itself as the market leader of online clinical information and
education solutions for physicians and healthcare professionals.
With the plethora of available information, patients are becoming
more educated on the prescription drugs they consume and require their
physician to have even greater levels of product knowledge. With time
at a premium, it is becoming increasingly difficult for physicians to
find time in the workday to gather the information they need to make
informed decisions at the point-of-care. PI e-Detailing(TM) brings
this information to the physician in a simple way that fits into their
schedule, utilizing the power of the Internet to connect physicians to
emerging clinical information through interactive educational programs
available 24 hours a day, 7 days a week.
“We are excited to be able to provide these services to BIPI,”
said Mark Thierer, President of the Physicians Interactive Group of
Allscripts. “Our vision is to develop innovative solutions that are
indispensable to physicians. PI e-Detailing provides physicians
anytime, anywhere access to educational programs on the latest
clinical studies, safety reports, and efficacy findings, delivering
the right information to support evidenced-based clinical decisions.”
The Physicians Interactive Group of Allscripts is the leading
provider of e-Detailing and other clinical information and patient
adherence solutions that connect healthcare providers to the forefront
of medicine. Allscripts has developed over 450 online programs for
more than 100 brands in every stage of the product life cycle.
Continuing its leadership in the industry, Allscripts works with more
than 50 pharmaceutical, biotech, and medical device clients, including
eight of the top 10 worldwide pharmaceutical firms.
About Boehringer Ingelheim Pharmaceuticals, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield,
CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation
(Ridgefield, CT) and a member of the Boehringer Ingelheim group of
companies.
The Boehringer Ingelheim group is one of the world’s 20 leading
pharmaceutical companies. Headquartered in Ingelheim, Germany, it
operates globally with 152 affiliates in 45 countries and more than
34,000 employees. Since it was founded in 1885, the family-owned
company has been committed to researching, developing, manufacturing
and marketing novel products of high therapeutic value for human and
veterinary medicine.
In 2003, Boehringer Ingelheim posted net sales of US $8.37 billion
(7.4 billion euro) while spending more than one fifth of net sales in
its largest business segment, Prescription Medicines, on research and
development.
For more information please visit www.boehringer-ingelheim.com.
About Allscripts
Allscripts Healthcare Solutions (Allscripts) is the leading
provider of clinical software, connectivity and information solutions
that physicians use to improve healthcare. The Company’s business
groups provide unique solutions that inform, connect, and transform
healthcare. The Clinical Solutions Group’s award-winning clinical
software applications include electronic health record (EHR),
e-prescribing and document imaging solutions. Additionally, Allscripts
provides clinical product education and connectivity solutions for
physicians and patients through its Physicians Interactive(TM) Group
and medication fulfillment services through its Medication Services
Group. Visit Allscripts on the Web at www.allscripts.com.
This announcement may contain forward-looking statements about
Allscripts Healthcare Solutions that involve risks and uncertainties.
These statements are developed by combining currently available
information with Allscripts beliefs and assumptions. Forward-looking
statements do not guarantee future performance. Because Allscripts
cannot predict all of the risks and uncertainties that may affect it,
or control the ones it does predict, Allscripts’ actual results may be
materially different from the results expressed in its forward-looking
statements. For a more complete discussion of the risks, uncertainties
and assumptions that may affect Allscripts, see the Company’s 2004
Annual Report on Form 10-K, available through the Web site maintained
by the Securities and Exchange Commission at www.sec.gov.
CONTACT: Allscripts
Dan Michelson, 312-506-1217
dan.michelson@allscripts.com
or
Physicians Interactive Group
Matthew Bloom, 847-680-3515, Ext.4650
matthew.bloom@allscripts.com
SOURCE: Allscripts